Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
Anna L. McNaughton, … , Sunetra Gupta, Craig P. Thompson
Anna L. McNaughton, … , Sunetra Gupta, Craig P. Thompson
Published May 24, 2022
Citation Information: JCI Insight. 2022;7(13):e156372. https://doi.org/10.1172/jci.insight.156372.
View: Text | PDF
Research Article Immunology Infectious disease

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

  • Text
  • PDF
Abstract

The role of immune responses to previously seen endemic coronavirus epitopes in severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and disease progression has not yet been determined. Here, we show that a key characteristic of fatal outcomes with coronavirus disease 2019 (COVID-19) is that the immune response to the SARS-CoV-2 spike protein is enriched for antibodies directed against epitopes shared with endemic beta-coronaviruses and has a lower proportion of antibodies targeting the more protective variable regions of the spike. The magnitude of antibody responses to the SARS-CoV-2 full-length spike protein, its domains and subunits, and the SARS-CoV-2 nucleocapsid also correlated strongly with responses to the endemic beta-coronavirus spike proteins in individuals admitted to an intensive care unit (ICU) with fatal COVID-19 outcomes, but not in individuals with nonfatal outcomes. This correlation was found to be due to the antibody response directed at the S2 subunit of the SARS-CoV-2 spike protein, which has the highest degree of conservation between the beta-coronavirus spike proteins. Intriguingly, antibody responses to the less cross-reactive SARS-CoV-2 nucleocapsid were not significantly different in individuals who were admitted to an ICU with fatal and nonfatal outcomes, suggesting an antibody profile in individuals with fatal outcomes consistent with an “original antigenic sin” type response.

Authors

Anna L. McNaughton, Robert S. Paton, Matthew Edmans, Jonathan Youngs, Judith Wellens, Prabhjeet Phalora, Alex Fyfe, Sandra Belij-Rammerstorfer, Jai S. Bolton, Jonathan Ball, George W. Carnell, Wanwisa Dejnirattisai, Christina Dold, David W. Eyre, Philip Hopkins, Alison Howarth, Kreepa Kooblall, Hannah Klim, Susannah Leaver, Lian Ni Lee, César López-Camacho, Sheila F. Lumley, Derek C. Macallan, Alexander J. Mentzer, Nicholas M. Provine, Jeremy Ratcliff, Jose Slon-Compos, Donal Skelly, Lucas Stolle, Piyada Supasa, Nigel Temperton, Chris Walker, Beibei Wang, Duncan Wyncoll, Oxford Protective T Cell Immunology for COVID-19 (OPTIC) consortium, Scottish National Blood Transfusion Service (SNBTS) consortium, Peter Simmonds, Teresa Lambe, John Kenneth Baillie, Malcolm G. Semple, Peter J.M. Openshaw, International Severe Acute Respiratory and emerging Infection Consortium Coronavirus Clinical Characterisation Consortium (ISARIC4C) investigators, Uri Obolski, Marc Turner, Miles Carroll, Juthathip Mongkolsapaya, Gavin Screaton, Stephen H. Kennedy, Lisa Jarvis, Eleanor Barnes, Susanna Dunachie, José Lourenço, Philippa C. Matthews, Tihana Bicanic, Paul Klenerman, Sunetra Gupta, Craig P. Thompson

×

Figure 4

In fatal COVID-19 outcomes, antibody responses to SARS-CoV-2 are highly correlated with antibody responses to the endemic beta-coronavirus spike proteins.

Options: View larger image (or click on image) Download as PowerPoint
In fatal COVID-19 outcomes, antibody responses to SARS-CoV-2 are highly ...
(A) Correlation between SARS-CoV-2 and endemic coronavirus responses. Spearman’s rank correlations (ρ) are shown for each pair of antigens, split by sample group. There is a positive correlation between all SARS-CoV-2 antigens in all cohorts exposed to SARS-CoV-2. Significant correlations are found between SARS-CoV-2 antigens and endemic beta-HCoVs (HCoV-OC43 and HCoV-HKU1) in the SARS-CoV-2 antibody-positive blood donor and antenatal groups as well as the ICU fatal outcome group. These correlations are absent in the asymptomatic and nonfatal outcome from severe COVID-19 groups. The correlation between endemic beta-HCoVs and SARS-CoV-2 antigens is considerably weaker in the larger positive blood donor and antenatal cohorts than in the ICU fatal outcome group. Responses to the SARS-CoV-2 spike (B) and RBD (C) correlate with beta-coronavirus spike responses in individuals with fatal COVID-19 outcomes. Correlations are shown with a linear model fit between the concentration of 2 SARS-CoV-2 antigens and the endemic viruses HCoV-OC43 and HCoV-HKU1. The best fit line is shown in blue with 95% confidence intervals in gray; the dotted gray division denotes a 1:1 response to both antigens. There is a strong positive association between SARS-CoV-2 spike/RBD and the endemic HCoVs in the fatal outcomes from severe COVID-19 group, which is absent in the similarly sized asymptomatic and nonfatal outcomes from severe COVID-19 groups.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts